ERBB2 and neoplasm: This discrepancy may reflect differences in the immune surveillance, tumor-infiltrating lymphocytes, therapy sensitivity, and/or HER2 amplification between the primary site and regional nodal basin, or disruption of the circulation to lymphatic tissue.28,38